Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance

Bar-Zeev, Maya; Livney, Yoav D.; Assaraf, Yehuda G.

doi:10.1016/j.drup.2017.05.002

Cited by 277 publications

(174 citation statements)

References 164 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…[13] In addition, hypoxia promotes resistance toward conventional cancer therapies, including chemotherapy, radiotherapy (RT), and photodynamic therapy (PDT; Figure 1). [14][15][16][17] Multiple mechanisms have been correlated with hypoxia-mediated resistance to chemotherapeutic drugs, including slow cell proliferation and over-expression of multidrug resistance gene 1 (MDR1) and the gene for the p-glycoprotein (p-gp) efflux pump. [18,19] The efficacy of RT and PDT is directly associated with the oxygen concentration.…”

Section: Doi: 101002/adtp201800026mentioning

confidence: 99%

Recent Progress in the Design of Hypoxia‐Specific Nano Drug Delivery Systems for Cancer Therapy

Sahu

Choi

Tae

2018

Advanced Therapeutics

View full text Add to dashboard Cite

Hypoxia is a salient feature in many solid tumors and an important player in tumor growth and progression. Increasing evidence suggests hypoxia plays major roles in the angiogenesis, metastasis, and resistance toward conventional cancer therapy treatments such as chemotherapy, radiotherapy, and photodynamic therapy. However, the exact reason that makes hypoxia a problem is also an opportunity for the development of new therapeutic modalities. The low oxygen level and highly reductive environment provide great options for stimuli-sensitive drug release in a highly target-specific manner. The use of nanoparticle-based systems for hypoxia-selective drug delivery is a relatively new but rapidly progressing research area. This report summarizes the recent trends and advances in the development of new hypoxia-specific nanomedicines. The background, the current progress, and what could be done in the future to achieve greater success in cancer therapy are discussed.

show abstract

Section: Doi: 101002/adtp201800026mentioning

confidence: 99%

Recent Progress in the Design of Hypoxia‐Specific Nano Drug Delivery Systems for Cancer Therapy

Sahu

Choi

Tae

2018

Advanced Therapeutics

View full text Add to dashboard Cite

show abstract

“…Finally, multidrug resistance (MDR) to anticancer drugs continues to hinder curative therapy of various human malignancies (35–39). MDR may arise from a variety of molecular mechanisms, such as new mutations in key target genes, dysregulation of normal apoptotic controls, or upregulation of chemoresistance due to multidrug efflux pumps of the ATP-binding cassette (ABC) superfamily such as P-glycoprotein (P-gp), which expel a wide spectrum of cytotoxic agents (40).…”

Section: Targeting Brain Metastasis With Cancer Immunotherapymentioning

confidence: 99%

Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance

Owyong

Hosseini-Nassab

Efe

et al. 2017

Drug Resistance Updates

View full text Add to dashboard Cite

The advent of cancer immunotherapy (CIT) and its success in treating primary and metastatic cancer may offer substantially improved outcomes for patients. Despite recent advancements, many malignancies remain resistant to CIT, among which are brain metastases, a particularly virulent disease with no apparent cure. The immunologically unique niche of the brain has prompted compelling new questions in immuno-oncology such as the effects of tissue-specific differences in immune response, heterogeneity between primary tumors and distant metastases, and the role of spatiotemporal dynamics in shaping an effective anti-tumor immune response. Current methods to examine the immunobiology of metastases in the brain are constrained by tissue processing methods that limit spatial data collection, omit dynamic information, and cannot recapitulate the heterogeneity of the tumor microenvironment. In the current review, we describe how high-resolution, live imaging tools, particularly intravital microscopy (IVM), are instrumental in answering these questions. IVM of pre-clinical cancer models enables short- and long-term observations of critical immunobiology and metastatic growth phenomena to potentially generate revolutionary insights into the spatiotemporal dynamics of brain metastasis, interactions of CIT with immune elements therein, and influence of chemo- and radiotherapy. We describe the utility of IVM to study brain metastasis in mice by tracking the migration and growth of fluorescently-labeled cells, including cancer cells and immune subsets, while monitoring the physical environment within optical windows using imaging dyes and other signal generation mechanisms to illuminate angiogenesis, hypoxia, and/or CIT drug expression within the metastatic niche. Our review summarizes the current knowledge regarding brain metastases and the immune milieu, presents the current status of CIT and its prospects in targeting brain metastases to circumvent therapeutic resistance, and proposes avenues to utilize IVM to study CIT drug delivery and therapeutic efficacy in preclinical models that will ultimately facilitate novel drug discovery and innovative combination therapies.

show abstract

“…Such materials are referred as nanotheranostics. Anchoring of the targeting ligand, such as organic molecules (such as folic acid or biotin) or biopolymers (such as immunoglobulins or nucleic acids), to the theranostic system further enables to focus the therapeutic effect on the cancer cells . The principle of such active targeting is in the selective binding of the nanotheranostic material into a tumor receptor.…”

Section: Introductionmentioning

confidence: 99%

“…Anchoring of the targeting ligand, such as organic molecules (such as folic acid or biotin) or biopolymers (such as immunoglobulins or nucleic acids), to the theranostic system further enables to focus the therapeutic effect on the cancer cells. [7][8][9][10] The principle of such active targeting is in the selective binding of the nanotheranostic material into a tumor receptor. The nanotheranostic species are attractive candidates in modern cancer chemotherapy because they increase the biocompatibility and bioaccessibility of the drug.…”

Section: Introductionmentioning

confidence: 99%

Folic Acid‐Navigated and β‐Cyclodextrin‐Decorated Carbon‐Encapsulated Iron Nanoparticles as the Nanotheranostic Platform for Controlled Release of 5‐Fluorouracil

et al. 2018

View full text Add to dashboard Cite

The theranostic probe based on carbon‐encapsulated iron nanoparticles (CEINs) is presented. First, the conjugates of CEINs and polyethylenimine (PEI) were obtained to modify the surface of CEINs with amino groups. It was archived either by means of direct radical addition of PEI to CEINs (CEINs‐NH‐PEI material) or the amidation‐type reaction between CEINs∼COOH and the polymer (CEINs∼CONH‐PEI material obtained). β‐Cyclodextrin (βCD) was selected as the drug delivery vector. βCD was covalently anchored to the PEI‐functionalized CEINs via the 1,1’‐carbonyldiimidazole‐mediated reaction. The synthesis included the conjugation of folic acid (FA; targeting ligand) to CEINs via the carbodiimide‐mediated amidation‐type process. The innovative method for excluding a side process of the FA@βCD complex formation during the FA conjugation to PEI, was developed. 5‐Fluorouracil (5‐FU) was chosen as the representative drug molecule. 5‐FU was anchored to the CEINs∼PEI∼βCD∼FA nanoplatforms employing the host‐guest chemistry of βCD. The success of the reactions was confirmed by infrared spectroscopy and thermogravimetry. The content of anchored organic compounds depends on the type of linkage between PEI and CEINs. Additionally, 5‐FU release profile was examined at various pH. The highest release of 5‐FU was observed at pH 9.0, whilst the lowest at pH 4.7. This work sheds a new light on application of carbon‐encapsulated iron nanoparticles in nanomedicine as the novel drug delivery theranostic systems.

show abstract

Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance

Cited by 277 publications

References 164 publications

Recent Progress in the Design of Hypoxia‐Specific Nano Drug Delivery Systems for Cancer Therapy

Recent Progress in the Design of Hypoxia‐Specific Nano Drug Delivery Systems for Cancer Therapy

Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance

Folic Acid‐Navigated and β‐Cyclodextrin‐Decorated Carbon‐Encapsulated Iron Nanoparticles as the Nanotheranostic Platform for Controlled Release of 5‐Fluorouracil

Contact Info

Product

Resources

About